Corticosteroids and Bone: a Review

Burckhardt, P.

doi:10.1159/000179975

Cited by 29 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…our patients have low bone formation markers and high bone resorption markers (Table II). We have found that vertebral Z-scores of our patients, which is a sensitive indicator to the effect of steroid therapy [23], are considered normal according to the World Health Organization [24]. Normal BMD in CAH patients has been reported earlier by other authors [13, 25, 26], who found that adolescents with CAH had BMD values comparable with controls, despite glucocorticoid treatment.…”

Section: Discussionsupporting

confidence: 62%

Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia

Dayem¹,

Anwar²,

Salama³

et al. 2010

aoms

View full text Add to dashboard Cite

IntroductionAim of this paper is to assess bone mineral density (BMD) and body composition, by dual energy X-ray absorptiometry (DXA), and various markers of bone growth, in a group of children with congenital adrenal hyperplasia (CAH) on long-term glucocorticoid therapy.Material and methodsA case-control study included thirty patients with CAH with different states of metabolic control. Their mean age was 7.5 ±4.2 years. All patients are subjected to BMD using DXA at the neck of the femur and lumbar spine. A blood sample was taken for assessment of osteocalcin, osteoprotegerin, and procollagen type 1, as markers of bone formation, as well as RANKL and urinary deoxypyridinoline (DPD), as markers of bone resorption.ResultsWe found no difference in BMD in patients and control subjects; however, patients showed significantly lower serum osteocalcin (p = 0.008) and osteoprotegerin (p = 0.0001) and significantly higher serum RANKL levels (p = 0.0001). Our results show that patients had significantly lower lean body mass (p = 0.005) and fat/lean ratio (p = 0.008) compared to matched controls. The duration of treatment showed a significant negative correlation with procollagen type 1 (r = –0.49, p = 0.02) and lean mass % (r = –0.43, p = 0.04); however, it showed a significant positive correlation with total fat mass % (r = 0.6, p = 0.0006), and fat/lean ratio (r = 0.43, p = 0.04). Dose of steroid had a significant positive correlation with BMI SDS (r = 0.4, p = 0.02).ConclusionsBone mineral density is normal but bone turnover is low in patients with CAH. There is an increase in fat/lean mass in patients with CAH.

show abstract

Section: Discussionsupporting

confidence: 62%

Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia

Dayem¹,

Anwar²,

Salama³

et al. 2010

aoms

View full text Add to dashboard Cite

show abstract

“…To date, the most recent guidelines include inhaled corticosteroids (ICSs) or systemic corticosteroids in the pharmacological management of patients with COPD in order to improve pulmonary symptoms during both the maintenance phase and exacerbations [ 32 ]. In this scenario, the recent literature has focused on the detrimental consequences of corticosteroid administration on bone mineral density (BMD) [ 33 ]. Despite these considerations, the molecular pathways involved in corticosteroid-induced osteoporosis are far from being fully characterized.…”

Section: Long-term Corticosteroids Therapy In Copd Patientsmentioning

confidence: 99%

Osteosarcopenia in Patients with Chronic Obstructive Pulmonary Diseases: Which Pathophysiologic Implications for Rehabilitation?

Lippi

Folli

Curci

et al. 2022

IJERPH

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a burdensome condition affecting a growing number of people worldwide, frequently related to major comorbidities and functional impairment. In these patients, several factors might have a role in promoting both bone and muscle loss, including systemic inflammation, corticosteroid therapies, sedentary behaviours, deconditioning, malnutrition, smoking habits, and alcohol consumption. On the other hand, bone and muscle tissues share several linkages from functional, embryological, and biochemical points of view. Osteosarcopenia has been recently defined by the coexistence of osteoporosis and sarcopenia, but the precise mechanisms underpinning osteosarcopenia in patients with COPD are still unknown. In this scenario, a deeper understanding of the molecular basis of osteosarcopenia might guide clinicians in a personalized approach integrating skeletal muscle health with the pulmonary rehabilitation framework in COPD. Taken together, our results summarized the currently available evidence about the multilevel interactions between osteosarcopenia and COPD to pave the way for a comprehensive approach targeting the most common risk factors of these pathological conditions. Further studies are needed to clarify the role of modern clinical strategies and telemedicine solutions to optimize healthcare delivery in patients with COPD, including osteopenia, osteoporosis, and sarcopenia screening in these subjects.

show abstract

“…The articular cartilage changes have been well documented in the horse, but also remain controversial, as some medications appear to be beneficial (Foland et al 1994;Frisbie et al 1995) and others appear harmful (Chunekamrai et al 1989;Trotter et al 1991). Systemic corticosteroid treatment is known to decrease bone formation and often lead to osteopenia in man (Burckhardt 1984;Peretz et al 1989). The effects of intraarticular administration of corticosteroids on systemic and local bone formation in horses are unknown.…”

Section: Introductionmentioning

confidence: 99%

Effects of osteochondral fragmentation and intra‐articular triamcinolone acetonide treatment on subchondral bone in the equine carpus

Kawcak

Norrdin

Frisbie

et al. 1998

Equine Veterinary Journal

View full text Add to dashboard Cite

Summary To determine the effects of osteochondral fragmentation and intra‐articular corticosteroid treatment on dynamics of bone remodelling and fragility, 12 horses each had a unilateral, 8 mm osteochondral fragment created in the distal aspect of one radiocarpal bone. Six of the horses were treated in the fragmented joint, and the other 6 were treated in the nonfragmented joint with 12 mg of triamcinolone acetonide (TA) 14 and 28 days after surgery. All horses were exercised on a high‐speed treadmill starting 15 days, and ending 72 days after surgery. Horses treated with TA in the fragmented joints were significantly less lame than those treated in the nonfragmented joints. Third carpal bones from joints with fragments showed significantly more vascularity, single labelled surface, total labelled surface and mineralising surface in subchondral and subjacent trabecular bone. Trends were also seen towards higher vascular canal volume and osteochondral junction remodelling sites in third carpal bones from fragmented joints. No significant differences were seen in microdamage density or size between fragmented and nonfragmented joints. No significant influence of TA treatment was seen on any parameter measured. The results from this study show that osteochondral fragmentation induces significant changes in remodelling of opposing bones, and that the administration of corticosteroids into joints with fragmentation does not significantly alter bone remodelling or fragility.

show abstract

Corticosteroids and Bone: a Review

Cited by 29 publications

References 32 publications

Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia

Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia

Osteosarcopenia in Patients with Chronic Obstructive Pulmonary Diseases: Which Pathophysiologic Implications for Rehabilitation?

Effects of osteochondral fragmentation and intra‐articular triamcinolone acetonide treatment on subchondral bone in the equine carpus

Contact Info

Product

Resources

About